Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06014086 · ClinicalTrials.gov registry record · Phase 1
Intratumoral PH-762 for Cutaneous Carcinoma
A Phase 1 study of Merkel Cell Carcinoma of Skin and Squamous Cell Carcinoma of the Skin, sponsored by Phio Pharmaceuticals.
- Active
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 5
- Study locations
NCT06014086: Active Phase 1 study of Merkel Cell Carcinoma of Skin and Squamous Cell Carcinoma of the Skin, sponsored by Phio Pharmaceuticals.
NCT06014086 is a Phase 1 study of Merkel Cell Carcinoma of Skin and Squamous Cell Carcinoma of the Skin that is active but no longer recruiting, run by Phio Pharmaceuticals. The registered enrollment target is 30 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06014086, a Phase 1 study of Merkel Cell Carcinoma of Skin and Squamous Cell Carcinoma of the Skin, is active but no longer recruiting, sponsored by Phio Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 5
- Study locations
Study Summary
The goal of this clinical trial is to evaluate the safety and tolerability of intratumoral injections of PH-762 in squamous cell carcinoma, melanoma, or Merkel cell carcinomas of the skin, to understand what the body does to the PH-762, and to observe how the tumor responds to the drug. Participants will receive four injections of PH-762 at weekly intervals, into a single tumor, followed by surgical removal of the tumor approximately two weeks later.
Primary Outcome
Incidence, severity, seriousness and relatedness of all treatment-emergent adverse events.
Conditions Studied
Interventions
- DRUG PH-762
Study Locations (5)
Arizona
- Banner MD Anderson Cancer Center - Gilbert
California
- Paradigm Clinical Research - San Diego
Florida
- Integrity Research - Delray Beach
Nevada
- Skin Cancer and Dermatology Institute - Reno
Ohio
- Centricity Research - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-11-07 |
| Est. Completion | 2026-03 |
| Phase | Phase 1 |
What the registry record for NCT06014086 still lists
NCT06014086 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower).
The record links to 3 conditions, with Merkel Cell Carcinoma of Skin appearing as the primary indexed condition, and to 1 intervention - of which PH-762 is the first listed.
NCT06014086 lists 5 locations in 5 states (Arizona, California, Florida).
Frequently Asked Questions
What is clinical trial NCT06014086 about?
NCT06014086 is a clinical study titled "Intratumoral PH-762 for Cutaneous Carcinoma". The goal of this clinical trial is to evaluate the safety and tolerability of intratumoral injections of PH-762 in squamous cell carcinoma, melanoma, or Merkel cell carcinomas of the skin, to understand what the body does to the PH-762, and to observe how the tumor responds to the drug. Participants...
What is the current status of trial NCT06014086?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2023-11-07. Estimated completion is 2026-03.
What conditions does trial NCT06014086 study?
This clinical trial studies the following conditions: Merkel Cell Carcinoma of Skin, Squamous Cell Carcinoma of the Skin, Malignant Melanoma of Skin.
What interventions are being tested in trial NCT06014086?
The interventions under investigation include: PH-762 (DRUG).
Who is sponsoring clinical trial NCT06014086?
This trial is sponsored by Phio Pharmaceuticals, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06014086 being conducted?
This trial has 5 study locations across Arizona, California, Florida, Nevada, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Merkel Cell Carcinoma of Skin
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06014086's enrollment target sits among peer trials
30 1332nd of 2000 higher than 561 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI